Blog

Company Invites Shareholders to Submit Questions to be Answered on the Webcast

TORONTO, ONTARIO / ACCESS Newswire / January 5, 2026 / New Horizon Aircraft Ltd. (NASDAQ:HOVR), doing business as Horizon Aircraft (“Horizon Aircraft” or the “Company”), an advanced aerospace engineering company and developer of one of the world’s first hybrid-electric VTOL (Vertical Take-Off and Landing) aircraft, announces that it will release its financial results for the fiscal second quarter of 2026 on Wednesday, January 14, 2026, at 8:30 am EST. Horizon Aircraft management will discuss those results and other information regarding the Company during a conference call and webcast.

The conference call may be accessed by telephone at 888-506-0062 from North America and at 973-528-0011 from international numbers (Access Code: 953458) or by joining the live webcast on Horizon Aircraft’s investor relations website at https://ir.horizonaircraft.com/events-presentations. An archive of the webcast will be available shortly after the call.

Horizon Aircraft invites shareholders to submit questions which will be answered on the webcast. Management will address select questions relating to its business and financial results and corporate and strategic plans. Questions should be submitted to hovr@fnkir.com by Friday, January 9, 2026. Investors submitting questions will also be added to the IR mailing list.

About Horizon Aircraft

Horizon Aircraft (NASDAQ:HOVR) is an advanced aerospace engineering company that is developing one of the world’s first hybrid-electric VTOL aircraft designed to fly most of its mission in traditional wing-borne flight, offering industry-leading speed, range, and operational utility. Horizon Aircraft’s unique designs put the mission first and prioritize safety, performance, and utility. Horizon Aircraft intends to successfully complete testing and certification of its Cavorite X7 and then scale unit production to meet expected demand from regional operators, emergency service providers, and military customers.

For further information, visit:

Website www.horizonaircraft.com
LinkedIn https://www.linkedin.com/company/horizon-aircraft-inc

For further information, contact:

Investors:
Kathryn Burns
ir@horizonaircraft.com

Media:

Edwina Frawley-Gangahar
EFG Media Relations
+44 7580 174672
edwina@efgmediarelations.com

SOURCE: Horizon Aircraft

View the original press release on ACCESS Newswire

Tax professionals warn that missing or incorrect 1099 forms do not prevent the IRS from calculating income and issuing tax bills.

IRVINE, CA / ACCESS Newswire / January 5, 2026 / Many taxpayers assume that if a 1099 form was never issued or received, the IRS has no basis to assess tax on that income. According to Clear Start Tax, a national tax resolution firm, that assumption can lead to costly surprises. The IRS can and does estimate income using alternative data sources, even when no formal 1099 has been filed.

Clear Start Tax explains that the IRS relies on a broad network of information, including bank records, payment processor reports, prior-year filings, and third-party data sharing. When income appears unreported, the agency may calculate what it believes a taxpayer earned and issue a tax assessment based on those estimates.

“We regularly hear from taxpayers who say, ‘There was no 1099, so the IRS can’t prove it,’” said a Clear Start Tax spokesperson. “In reality, the IRS often estimates income using whatever information it has available – and those estimates tend to favor the government, not the taxpayer.”

In many cases, estimated assessments occur when returns are filed late or not at all. The IRS may create a substitute return that excludes business expenses, deductions, or credits, resulting in a higher tax bill than the taxpayer would owe if they filed accurately.

Clear Start Tax notes that contractors, freelancers, and cash-based earners are especially at risk. Even partial reporting or inconsistent income patterns can trigger IRS scrutiny and lead to estimated assessments that are difficult to reverse without proper documentation.

“Once the IRS makes an assessment, the burden shifts to the taxpayer to prove it’s wrong,” the spokesperson added. “That’s much harder than reporting income correctly from the start.”

Tax professionals emphasize that filing a complete and accurate return – even when income documentation is incomplete – is often the best way to prevent inflated IRS estimates and preserve access to relief options.

With IRS enforcement efforts increasing, Clear Start Tax encourages taxpayers with unreported or undocumented income to address the issue proactively rather than assume it will go unnoticed.

“Silence doesn’t stop the IRS from acting,” the spokesperson said. “It often gives them more room to estimate – and estimate high.”

By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt.

About Clear Start Tax
Clear Start Tax is a national tax resolution firm that assists individuals and businesses with IRS and state tax issues, including unfiled returns, back taxes, and collection actions. The firm focuses on helping taxpayers understand IRS procedures and pursue appropriate resolution strategies based on their circumstances.

Need Help With Back Taxes?
Click the link below:
https://clearstarttax.com/qualifytoday/
(888) 710-3533

Contact Information
Clear Start Tax
Corporate Communications Department
tech@clearstarttax.com
(949) 800-4011

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire

Partnership pairs Datavault AI’s patented DataValue^®, DataScore^® and Information Data Exchange^® (IDE^®) solutions with Available Infrastructure’s SanQtum™ cybersecure high performance points of presence designed to support near-real-time tokenization, data exchange, and agentic monetization that will provide Datavault AI the foundation to scale enterprise adoption of its AI while also solving for requisite regulatory compliance for its IDE^®

Quantum Key Encryption from SanQtum will further differentiate patented and forthcoming Datavault AI IDE deployments with Elements Exchange (RWA), NIL and American Political Exchanges set to Launch Q1 2026, that will be quantum ready

33 Top cities in US will begin with systems integration of patented Data Vault, DataScore, IDE and Available Infrastructure’s SanQtum cybersecurity for private high performance computing in the Datavault AI Edge Network

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 5, 2026 / Datavault AI (“Datavault AI” or the “Company”) (Nasdaq:DVLT) a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies today announced a nationwide planned deployment of SanQtum in partnership with AP Global Holdings LLC (d/b/a Available Infrastructure) to enable secure communications, encrypted storage, and high-performance data processing across 100 cities throughout the contiguous United States. Built to support Datavault AI’s patented IDE, which helps turn raw data into tradable assets, this deployment is designed to deliver lower latency, stronger cyber protection, and consistent performance across distributed environments.

By combining Datavault AI’s RWA tokenization with Available Infrastructure’s distributed architecture, the companies aim to deliver secure points of presence that support workflows where speed, integrity, and trust are essential. Datavault AI’s IDE helps create a digital twin of a physical asset by linking it to a permanent, tamper-resistant record, stored as immutable metadata or on a blockchain. As the nationwide deployment scales, the companies expect the combined footprint to accelerate trusted tokenization, exchange, and valuation by placing secure data processing closer to where data is created and decisions are made.

“Performance and presence in this precursor to true quantum computing starts with command of our own and the first virtual private network that will rival power-strapped bulky data center build outs with a redundant, cybersecure cluster of Available Infrastructure’s SanQtum and Datavault AI servers that can do more with less power consumption and absent the burden of coolant required of legacy systems,” said Nathaniel Bradley, CEO, Datavault AI. “This deployment advances our ability to achieve true immutability of digital objects through Quantum Key Encryption that is foundational to support high-integrity zero-trust tokenization. Our coming and market superior data exchange with hundreds of tokenomic use cases will provide first-of-its-kind secure infrastructure positioned closer to the point of need. We have an opportunity to really impact our customers’ bottom lines while bolstering our industry lead and making access to super compute power sustainable and obtainable by companies of all sizes and in markets of our choosing, starting here in the United States the most lucrative.”

“SanQtum provides the cybersecurity vault for Datavault AI. With edge compute projected to grow at a nearly 30% CAGR through 2033, now is the time to build Datavault AI’s sovereign cloud at the nation’s edge. In our preliminary estimation, each network location has a servicable addressable market (SAM) potential exceeding $100 million per annum driven by regional demand for high performance computing applications including digital twins and data monetization, making Datavault AI our ideal partner,” stated Daniel C. Gregory, CEO of Available Infrastructure. “Through SanQtum, we are deploying secure edge nodes built for high availability and ultra-low latency with zero trust controls, enabling Datavault AI to bring trusted quantum encrypted tokenization, exchange, and valuation to the edge, at national scale.”

Following the initial rollout, Datavault AI and Available Infrastructure will align deployment standards and operational tooling to connect Datavault capabilities, focused on real-time data observation, market capture, valuation, and secure, encrypted monetization of data assets, to a national footprint of hardened edge locations. This footprint enables customers to collect and process data closer to the point of creation, then generate permanent records, confirm identity, and connect RWAs to immutable blockchain entries at the speed of operations.

Datavault AI: Patent-Backed tokenization and Data-provenance capabilities
Datavault AI is a technology and patent portfolio-driven company positioned in RWA tokenization through a strategic licensing model and through a platform that helps organizations connect RWAs to immutable blockchain records for traceability, authenticity, and monetization. The Company highlights its exchange platform as a foundation for securely attaching physical real-world objects to immutable metadata or blockchain objects, supporting use cases such as digital twins and “responsible AI with integrity,” while also enabling integration with compliant blockchains to create tokenized solutions tailored to customer needs.

Available Infrastructure: Secure, Highly Available, Distributed Platform

Available Infrastructure will provide the distributed solution through SanQtum, a real-time edge platform that bundles edge cloud services and zero trust cybersecurity in a single platform. SanQtum will operate across distributed micro data centers in, and around, major metropolitan areas and urban centers. SanQtum pre-integrates a technology stack in a micro edge data center form factor, ready for deployment from near-prem urban sites to telecom towers to austere environments, to run intelligent, sovereign workloads directly at the edge without sending data back to the cloud.

Urban sites and other on-prem and near-prem edge locations plus fiber optic communications can deliver ultra-low latency in supported configurations. SanQtum applies a CISA-compliant zero trust approach and NIST-approved quantum-resilient encryption. Its multi-site architecture spans multiple locations and communications paths, including in-ground fiber optic, SATCOM, and a wireless self-healing mesh, with resilient backup power to support operational resilience and continuity.

Deployment highlights

• Secure communications with standardized controls across distributed sites

• Secure storage and near-edge compute positioned closer to operations and data sources

• Secure data processing designed for performance-sensitive and mission-critical workflows

• Zero trust, quantum-resilient protection in private mesh environments

• High availability and continuity supported by multi-site, multi-channel architecture

Looking Ahead

Datavault AI and Available Infrastructure look forward to expanding this national rollout and supporting additional customer deployments that benefit from secure communications, secure storage, near-edge compute, and secure data processing. As coverage scales across the U.S., the companies expect the combined infrastructure footprint to help accelerate trusted tokenization, exchange, and valuation workflows by placing cybersecure edge nodes closer to where data is generated and decisions are made.

About Datavault AI
Datavault AI^TM (Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI’s cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at www.dvlt.ai.

About Available Infrastructure
Based in Northern Virginia along the Washington, DC, beltway, Available Infrastructure combines national security-grade, zero trust cyber protection and AI-powered, quantum-ready edge computing into an integrated edge solution for critical infrastructure, sensitive data, and enterprise AI models. For more information, please visit https://availableinfrastructure.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws) about Datavault AI Inc. (“Datavault AI,” the “Company,” “us,” “our,” or “we”) and our industry that involve risks and uncertainties. In some cases, you can identify forward-looking statements because they contain words, such as “may,” “might,” “will,” “shall,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “goal,” “objective,” “seeks,” “likely” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. The absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements, including, but not limited to, statements regarding future events, the expected benefits of the partnership with Available Infrastructure, anticipated deployment of the Company’s secure high-performance data processing capabilities across 100 cities throughout the contiguous Unites States, the timing, scope, and expected benefits of the national rollout, the performance and impact of the near-edge architecture and secure networking on-ramps, anticipated customer adoption and use cases (including tokenization, data exchange, and valuation), and expected operational, technical, and commercial outcomes, are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Readers are cautioned not to place undue reliance on these and other forward-looking statements contained herein.

Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties including, but not limited to, the following: change in market demand for secure high-performance data processing; the performance, timing, or success of the deployment of the Company’s secure high-performance data processing capabilities and ability to turn raw data into tradeable assets; changes in economic, market, or regulatory conditions; uncertainties regarding valuation methodologies and third-party reports; risks relating to evolving regulatory frameworks applicable to tokenized assets; risks associated with technological development and integration; and other risks and uncertainties as more fully described in Datavault AI’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 and other filings that Datavault AI makes from time to time with the SEC, which are available on the SEC’s website at www.sec.gov, and could cause actual results to vary from expectations.

The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. Datavault AI undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. Datavault AI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Datavault AI’s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments it may make.

Media Contacts

Datavault AI Inc
info@dvlt.ai

Available Infrastructure
Kiersten Hileman
Kiersten.hileman@availableinfra.com
VP Strategic Partnerships
786.797.7543

SOURCE: Datavault AI Inc

View the original press release on ACCESS Newswire

SAN BERNARDINO, CALIFORNIA / ACCESS Newswire / January 5, 2026 / Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF)(FSE:YE1) is pleased to announce the appointment of two highly respected North American mining executives, Mr George Brack and Mr Phillips Baker Jr, to its Board as Non-Executive Directors. These appointments strengthen Dateline’s U.S. presence and augments the Board’s expertise as the Company progresses its growth strategy focused on gold and critical minerals in North America.

Highlights

• George Brack and Phillips Baker Jr appointed as Non-Executive Directors of Dateline Resources.

• Highly experienced North American mining executives: Mr Brack brings 30+ years of mining finance and corporate development experience (including 16 years with Wheaton Precious Metals), while Mr Baker Jr served 23 years as Chief Executive Officer of Hecla Mining.

• Appointments align with Dateline’s strategy to advance the Colosseum Gold-REE Project and expand the Company’s presence in North America, adding valuable expertise ahead of expected project development.

Mr George Brack is a mining executive and finance professional with over 30 years of experience in the North American mining sector. He is currently the Chair of the Board of Wheaton Precious Metals (WPM), where he has served for the past 16 years. Mr Brack’s previous directorships include serving as Chair or director of multiple successful mining companies – including Capstone Copper (CS) (Lead Independent Director until 2023) and Red Back Mining amongst others. Mr Brack’s career has included senior positions in mining investment banking and corporate development, including as Vice President of Corporate Development at Placer Dome, with a focus on strategic mergers and acquisitions and project financing.

Mr Phillips Baker Jr is a highly regarded U.S. mining leader with 30 years of executive experience. He was the Chief Executive Officer of Hecla Mining Company (NYSE: HL) for 23 years (2001-2024) and served on Hecla’s Board during that period. Under his leadership, Hecla grew into the largest primary silver producer in the United States and expanded its portfolio with long-life gold assets, including the Casa Berardi mine in Quebec. In 2017, Mr Baker was awarded the William Lawrence Saunders Gold Medal by the American Institute of Mining, Metallurgical, and Petroleum Engineers (AIME), recognizing his significant contributions to the industry.

Dateline’s Chairman, Mark Johnson AO, said: “We are delighted to welcome two highly respected mining executives to Dateline’s Board. Mr. Baker’s experience leading Hecla Mining and Mr. Brack’s extensive background in mining finance and corporate strategy are exactly what we need as we advance the Colosseum Project towards production. Their North American experience and proven leadership will be valuable in helping realise the full potential of the Colosseum Project and our broader critical minerals objectives in the U.S. These appointments significantly bolster our Board, and with our Board now strengthened it will provide support for our Managing Director, Stephen Baghdadi.”

George Brack said: “When I was approached about this role, I recognised the opportunity that Colosseum presents. Having worked for many decades in the mining industry, I can see that Colosseum has all the ingredients to become a successful operation. I look forward to working with the Dateline team to complete the feasibility work and help bring the Colosseum Project into production, delivering value for shareholders.”

Phillips Baker Jr said: “After studying Dateline and its gold and critical minerals projects, I formed the opinion that this is an exciting development opportunity, with significant growth potential. There is no better time to be advancing a U.S. gold and rare earths project, and I look forward to helping Dateline move the Colosseum into production.”

This press release has been authorized for release by the Board of Dateline Resources Limited.

For more information, please contact:

Stephen Baghdadi
Managing Director
+61 2 9375 2353

Andrew Rowell
Corporate & Investor Relations Manager
+61 400 466 226
a.rowell@dtraux.com
www.datelineresources.com.au

Follow Dateline on socials:
X – @Dateline_DTR
Truth Social – @dateline_resources
LinkedIn – dateline-resources
YouTube – @dateline.resources

About Dateline Resources Limited

Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF)(FSE:YE1.F) is an Australian company focused on mining and exploration in North America. The Company owns 100% of the Colosseum Gold-REE Project in California.

The Colosseum Gold Mine is located in the Walker Lane Trend in East San Bernardino County, California. On 6 June 2024, the Company announced to the ASX that the Colosseum Gold mine has a JORC-2012 compliant Mineral Resource estimate of 27.1Mt @ 1.26g/t Au for 1.1Moz. Of the total Mineral Resource, 455koz @ 1.47/t Au (41%) are classified as Measured, 281koz @1.21g/t Au (26%) as Indicated and 364koz @ 1.10g/t Au (33%) as Inferred.

On 23 May 2025, Dateline announced that updated economics for the Colosseum Gold Project generated an NPV6.5 of US$550 million and an IRR of 61% using a gold price of US$2,900/oz.

The Colosseum is located less than 10km north of the Mountain Pass Rare Earth mine. Planning has commenced on drill testing the REE potential at Colosseum.

Dateline has also acquired the high-grade Argos Strontium Project, also located in San Bernadino County, California. Argos is reportedly the largest strontium deposit in the U.S. with previous celestite production grading 95%+ SrSO4.

Forward-Looking Statements

This announcement may contain “forward-looking statements” concerning Dateline Resources that are subject to risks and uncertainties. Generally, the words “will”, “may”, “should”, “continue”, “believes”, “expects”, “intends”, “anticipates” or similar expressions identify forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond Dateline Resources’ ability to control or estimate precisely, such as future market conditions, changes in regulatory environment and the behavior of other market participants. Dateline Resources cannot give any assurance that such forward-looking statements will prove to have been correct. The reader is cautioned not to place undue reliance on these forward-looking statements. Dateline Resources assumes no obligation and does not undertake any obligation to update or revise publicly any of the forward-looking statements set out herein, whether as a result of new information, future events or otherwise, except to the extent legally required.

Competent Person Statement

Sample preparation and any exploration information in this announcement is based upon work reviewed by Mr Greg Hall who is a Chartered Professional of the Australasian Institute of Mining and Metallurgy (CP-IMM). Mr Hall has sufficient experience that is relevant to the style of mineralization and type of deposit under consideration and to the activity which he is undertaking to qualify as a Competent Person as defined in the 2012 Edition of the “Australasian Code for Reporting Exploration Results, Mineral Resources and Ore Reserves” (JORC Code). Mr Hall is a Non-Executive Director of Dateline Resources Limited and consents to the inclusion in the report of the matters based on this information in the form and context in which it appears.

Company Confirmations

The Company confirms it is not aware of any new information or data that materially affects the information included in the announcements dated 23 October 2024 with regard to the Colosseum MRE and 23 May 2025 with regard to Colosseum Project Economics. Similarly, the Company confirms that all material assumptions and technical parameters underpinning the estimates and the forecast financial information referred to in those previous announcements continue to apply and have not materially changed.

SOURCE: Dateline Resources Limited

View the original press release on ACCESS Newswire

AI-native platform turns existing marketing stack into an intelligent system that learns from every campaign

LAS VEGAS, NV / ACCESS Newswire / January 5, 2026 / Stagwell (NASDAQ:STGW), the challenger network built to transform marketing, today announced the launch of “The Machine,” marketing’s first agentic operating system. Built by Code and Theory, Stagwell’s digital transformation agency and Adweek’s Most Innovative Agency of the Year, The Machine doesn’t replace marketers’ tools; it makes them more effective and predictive.

The Machine enhances the data systems and tools marketers already use, including Figma, Slack, Teams, Adobe, and performance dashboards. The Machine turns disconnected workflows into a unified system powered by AI agents and amplified by Stagwell’s agencies, products and data. With The Machine, every brief, creative asset and media plan feeds a system that learns, adapts and compounds. Each campaign makes the next one faster, smarter and more effective.

“The launch of The Machine, combined with our recent release of newvoices.AI and strategic partnerships with Palantir and Gradial, marks another milestone in cementing Stagwell as a leader in marketing AI,” said Mark Penn, Chairman and CEO of Stagwell. “This moment underscores Stagwell’s ability to deliver best-in-class solutions for clients and lead the industry through the AI era.”

“Most marketing AI tools ask you to rip out your infrastructure and start over,” said Dan Gardner, Founder and Chairman of Code and Theory. “The Machine does the opposite. It works where you work, improves and AI enables the tools you already use, and transforms existing operations into an agentic system. That’s the shift from isolated tools to a unified operating system.”

Code and Theory clients are already adopting The Machine’s early model. Stagwell will offer demos of The Machine at CES January 6-9 at booth #L2-P2, where attendees will see real use cases across the marketing organization, including:

• Cross-functional orchestration: Strategy, creative, production and media work from shared intelligence rather than siloed handoffs, reducing friction and accelerating time to market.

• Intelligence in context: Mini-Machine plugins directly into the tools marketers already in use, eliminating app-switching and workflow friction.

• Unified strategic spine: The Machine connects brand strategy, creative production and media performance into a single source of truth, ensuring every new campaign builds on what has already been learned.

• Creative content production at scale: AI-assisted workflows maintain brand integrity while dramatically increasing output velocity.

• Real-time tracking: Feeds into creative and strategic decisions, creating a closed loop where optimization happens continuously.

The Machine represents the culmination of Code and Theory’s work transforming marketing operations for enterprise clients including Qualcomm, TIME, Stanley Black & Decker, Henry Schein and T. Rowe Price. The agency’s historic 2024 included 11 top industry recognitions from Fast Company, Adweek, Ad Age, the ANA, Digiday, Campaign and the Shorty Awards.

“Clients have been asking for a solution that connects people, content, data, and technology to truly realize the value of AI, and The Machine delivers just that,” said Michael Treff, CEO of Code and Theory. “We’ve turned marketing operations into a unified system rather than a collection of tools to enable marketers to embrace the next phase of AI transformation.”

The Machine will be available for enterprise deployment in Q1 2025.

About Stagwell
Stagwell is the challenger holding company built to transform marketing. We deliver scaled creative performance for the world’s most ambitious brands, connecting culture-moving creativity with leading-edge technology to harmonize the art and science of marketing. Led by entrepreneurs, our specialists in 45+ countries are unified under a single purpose: to drive effectiveness and improve business results for our clients. Join us at www.stagwellglobal.com.

About Code and Theory
The Code and Theory Network is the only technology and creative network with a balance of 50% creative and 50% engineers. Our unique makeup makes us the place where CMOs, CTOs and CIOs come together to drive results for their businesses. We partner with our clients to redefine what is possible to create lasting impact and drive long-term growth. Part of Stagwell, Code and Theory offers a global footprint and the capabilities to work across the entirety of the customer-facing journey, and implement the technology that powers it. The network includes the flagship agency Code and Theory as well as Kettle, Instrument, Left Field Labs, Truelogic, Create. Group, Rhythm and Mediacurrent. Code and Theory clients include Amazon, JPMorganChase, Microsoft, NBC, NFL and Yeti. For more, visit codeandtheory.com.

Contact:
pr@stagwellglobal.com

SOURCE: Stagwell

View the original press release on ACCESS Newswire

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread.

MIAMI, FLORIDA / ACCESS Newswire / January 5, 2026 / Telomir Pharmaceuticals (NASDAQ:TELO) (“Telomir” or the “Company”), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of diseases, today announced results from a completed efficacy study evaluating Telomir-1 (Zn-Telomir) in zebrafish tumor xenograft animal models of triple-negative breast cancer (TNBC). The study was conducted in collaboration with BioReperia using its ZTX^® ONCOLEADS platform.

In one of these animal models, Telomir-1 demonstrated statistically significant reductions in primary tumor growth and in the spread of cancer cells beyond the primary tumor (metastatic dissemination) in an aggressive TNBC model with limited responsiveness to the chemotherapy agent paclitaxel. In a separate aggressive TNBC model where paclitaxel demonstrated antitumor activity, Telomir-1 produced a comparable reduction in primary tumor growth as a monotherapy, and the combination treatment with Telomir-1 and paclitaxel resulted in greater tumor growth inhibition than either agent alone.

To visually illustrate these findings, representative images from BT549 xenografts and the HCC1806 metastases model are shown below, highlighting both primary tumor size and cancer cell spread following treatment with Telomir-1.

Representative Images: Primary Tumor Growth (BT549 xenografts) and Cancer Cell Spread (HCC1806 Cells)

Representative zebrafish tumor xenograft images from the BT549 xenografts and HCC1806 triple-negative breast cancer models illustrating (A) primary BT549 xenografts tumor size and (B) cancer cell spread (metastatic dissemination) of HCC1806 cells. Images compare untreated control tumors with tumors treated with Telomir-1, demonstrating reduced primary tumor burden and reduced dissemination of cancer cells beyond the primary tumor site. Images are representative of quantified and statistically analyzed results reported in this study.

Study Design Overview

The study evaluated Telomir-1 administered alone and in combination with paclitaxel, a commonly used chemotherapy agent, on primary tumor growth and cancer cell spread in TNBC models. Human TNBC cells were implanted into zebrafish embryos and assessed over a three-day treatment period. Tumor size and cancer cell dissemination were quantified using fluorescent imaging and analyzed relative to vehicle-treated controls.

Three biologically distinct TNBC cell line-derived tumor models were evaluated to reflect the well-established heterogeneity of triple-negative breast cancer.

Why Triple-Negative Breast Cancer Is Not a Single Disease

Although triple-negative breast cancer is often discussed as a single clinical indication, it is now well recognized as a biologically heterogeneous disease, comprising multiple molecular subtypes with distinct drivers and treatment sensitivities.

Large genomic and transcriptomic studies have shown that TNBC can be divided into four to six major subtypes, including tumors that are initially chemotherapy-sensitive and others that are invasive and broadly treatment-resistant. As a result, no single therapy is expected to demonstrate uniform activity across all TNBC tumors, and variability in therapeutic response is an established feature of the disease.

From a drug-development perspective, this heterogeneity underscores the importance of treatment personalization, matching therapeutic mechanisms to tumor biology rather than pursuing unselected TNBC populations.

Tumor Model-Specific Results and Prevalence Context

BT-549 TNBC Model – Aggressive, Chemotherapy-Sensitive Subtype The BT-549 model represents an aggressive TNBC subtype with partial sensitivity to chemotherapy. In the current study, Telomir-1 and paclitaxel each produced statistically significant and broadly comparable reductions in primary tumor size when administered as monotherapies, with no statistically significant difference observed between the two agents. Combination treatment of low dose Telomir-1 and paclitaxel resulted in significantly greater tumor growth inhibition than either agent alone.

Based on published molecular subtype analyses, TNBC subtypes with biological features similar to BT-549 are estimated to represent approximately 30-40% of TNBC cases.

HCC1806 TNBC Model – Aggressive Subtype with Limited Chemotherapy Responsiveness The HCC1806 model represents an aggressive TNBC basal-subtype characterized by limited responsiveness to chemotherapy and a high propensity for cancer cell spread. In this model, paclitaxel did not produce statistically significant effects on primary tumor growth or on the spread of cancer cells beyond the primary tumor. In contrast, Telomir-1 treatment resulted in statistically significant reductions in primary tumor size at specific concentrations and statistically significant reductions in metastatic dissemination at an optimal concentration. Combination treatment further enhanced tumor growth inhibition compared to Telomir-1 monotherapy.

According to published molecular subtype analyses, TNBC subtypes with biological features similar to HCC1806, together with BT-549-like tumors, are estimated to account for approximately 40-60% of all TNBC cases.

MDA-MB-231 TNBC Model – Broadly Treatment-Resistant Subtype The MDA-MB-231 model represents a broadly treatment-resistant TNBC subtype is reported to exhibit tighter regulation of intracellular metal availability and strong intrinsic defense mechanisms. In this model, neither Telomir-1 nor the chemotherapy agent paclitaxel produced statistically significant effects on primary tumor growth or on the spread of cancer cells beyond the primary tumor.

TNBC subtypes with biological features similar to this model are estimated to represent approximately 15-25% of TNBC cases.

Mechanistic Interpretation: Iron, Copper, and Epigenetic Regulation

The differential responses observed across TNBC tumor models in this study are consistent with established differences in how these tumors regulate iron, copper, and epigenetically controlled gene activity.

TNBC models in which Telomir-1 demonstrated statistically significant effects are known, based on published literature, to rely on readily available intracellular iron and copper to support rapid growth and epigenetically regulated transcriptional programs. In these tumors, perturbation of metal availability is associated with measurable effects on tumor growth and cancer cell spread.

By contrast, the non-responsive TNBC model tightly controls and stores intracellular iron and copper and relies less on metal-regulated epigenetic flexibility. This biological profile is associated with reduced sensitivity to therapies that act through metal-dependent regulatory pathways and is consistent with the lack of response observed with both Telomir-1 and chemotherapy in this model.

Taken together, these findings indicate that Telomir-1 activity in this animal model is specific and dependent on underlying tumor biology and aligns with established differences among TNBC subtypes, rather than reflecting uniform or nonspecific anti-tumor effects.

Conclusion

· Telomir-1 demonstrated statistically significant tumor growth inhibition in aggressive TNBC models representing an estimated 40-60% of TNBC cases.

· Telomir-1 demonstrated statistically significant reduction in cancer cell spread in an aggressive TNBC model with limited chemotherapy responsiveness.

· In a broadly treatment-resistant TNBC subtype representing an estimated 15-25% of cases, neither Telomir-1 nor chemotherapy produced measurable effects, underscoring the biological specificity of response and providing important guidance for patient selection and clinical trial design.

· Combination treatment with paclitaxel enhanced tumor growth inhibition in models responsive to Telomir-1.

Importantly, the observed biology-driven activity and lack of effect in broadly treatment-resistant models provide valuable guidance for patient selection and trial design, which may improve the likelihood of observing clear clinical benefit in future studies.

Management Commentary

“These results demonstrate biologically consistent anti-tumor and anti-cancer spread activity in aggressive triple-negative breast cancer animal models, including tumors with limited responsiveness to standard chemotherapy, while also providing clear insight into the patient populations most likely to benefit in future clinical trials,” said Erez Aminov, CEO of Telomir.

“From a scientific perspective, this study provides important validation that targeting iron- and copper-regulated epigenetic pathways can translate into measurable effects on both tumor growth and metastatic behavior in relevant TNBC subtypes,” said Dr. Itzchak Angel, Chief Scientific Advisor at Telomir. “The alignment between mechanism and observed biology strengthens confidence as the program advances toward clinical development.”

Next Steps

Telomir is advancing Telomir-1 through ongoing IND-enabling activities and is actively preparing the data package required to support a future Investigational New Drug (IND) submission. In parallel, the Company is refining indication selection and patient population strategies based on accumulated preclinical evidence to support regulatory readiness and informed clinical development planning.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical biotechnology company developing small-molecule therapeutics designed to target the root epigenetic mechanisms underlying cancer, aging, and degenerative disease. The Company’s lead candidate, Telomir-1, has demonstrated activity in preclinical studies involving modulation of DNA and histone methylation, restoration of redox balance, and normalization of cellular function.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Email: info@telomirpharma.com Phone: (786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc

View the original press release on ACCESS Newswire